January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06844383 |
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate |
RECRUITING | PHASE2 |
| NCT05873192 |
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer |
RECRUITING | PHASE2 |
| NCT05327010 |
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial |
RECRUITING | PHASE2 |
| NCT05071937 |
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer |
RECRUITING | PHASE2 |
| NCT05059522 |
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04550494 |
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04334941 |
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04039230 |
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT02912572 |
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02286687 |
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes |
ACTIVE_NOT_RECRUITING | PHASE2 |
